Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE:MDT) announced it will report its financial results for Q3 FY2023 on February 21, 2023, at 5:45 a.m. CST. The results will cover the period ending January 27, 2023. The company will host a video webcast at 7:00 a.m. CST on the same day to discuss the results, accessible on its investor relations website. Additionally, Medtronic plans to announce its Q4 and full fiscal year 2023 results on May 25, 2023, with subsequent quarterly results for FY2024 scheduled throughout the year. The forward-looking statements are subject to risks, as disclosed in their periodic SEC filings.
Medtronic highlights its commitment to diversity and inclusion in STEM fields during Black History Month, emphasizing its partnership with the Thurgood Marshall College Fund (TMCF). This collaboration has resulted in the hiring of 64 interns since 2020, as well as a multi-year scholarship program for HBCU students, which has awarded over 100 scholarships to date. The focus is on fostering a diverse talent pipeline that is essential for innovation in healthcare technology. Medtronic's African Descent Network further supports this initiative by providing mentorship and professional development opportunities, aiming to enhance representation in the STEM workforce.
Medtronic (NYSE: MDT) released late-breaking results from the STROKE AF clinical study, highlighting the effectiveness of the Reveal LINQ™ insertable cardiac monitor (ICM) in detecting atrial fibrillation (AF) among ischemic stroke patients. At three years, AF detection was 21.7% in the ICM cohort compared to just 2.4% in standard care, showing a 10-fold increase. The study also revealed that 67% of patients with AF had episodes longer than one hour, with most being asymptomatic. The data underscore the necessity of long-term continuous cardiac monitoring in preventing subsequent strokes, particularly for high-risk groups.
Medtronic released its Global Inclusion, Diversity & Equity 2022 Annual Report, highlighting its commitment to addressing systemic inequities. CEO Geoff Martha emphasized the need to extend efforts beyond the workplace to impact community barriers. Key initiatives include:
- Diversity in STEM: Strengthening partnerships with organizations like the Thurgood Marshall College Fund.
- Breaking Education Barriers: Updating job requirements to prioritize skills over degrees, launching the MAPS program for college tuition coverage.
- Diverse Talent Recognition: Expanding benefits for LGBTQ+ and Black employees.
Medtronic aims for zero barriers to equity and increased innovation through diversity.
On January 25, 2023, Medtronic plc (NYSE:MDT) announced that it opposes an unsolicited mini-tender offer from TRC Capital Investment Corporation. TRC aims to purchase up to 1,500,000 Medtronic shares at
Medtronic strongly advises shareholders not to tender their shares, highlighting the risks of accepting below-market offers. The mini-tender process allows TRC to bypass many SEC requirements. The offer is set to expire on
Medtronic is enhancing its commitment to health equity by joining the Global Health Equity Network (GHEN) and signing the Zero Health Gaps Pledge. This initiative emphasizes collaboration with public and private sectors to address healthcare disparities affecting marginalized populations. Medtronic LABS aims to deliver tech-enabled healthcare solutions, having reached over 1 million patients. The company has committed $2.7 billion in purchases from small and diverse-owned businesses in FY23, focusing on driving economic opportunities and better health outcomes.
Ra Medical Systems has completed a stock-for-stock merger with Catheter Precision, aimed at enhancing its cardiac electrophysiology market presence. David Jenkins, CEO of Catheter Precision, will serve as Executive Chairman. The transaction includes a conversion of $25 million in debt to non-voting Convertible Preferred Stock, granting Catheter Precision stakeholders approximately 87.7% of RMED’s equity. Ra Medical anticipates raising up to
Medtronic plc (NYSE:MDT) will participate in the 41st annual J.P. Morgan healthcare conference on January 9, 2023. CEO Geoff Martha is scheduled to present at 9:00 a.m. PST (11:00 a.m. CST). Following the presentation, key executives including CFO Karen Parkhill will engage in a Q&A session. A live webcast of the event will be available on the company’s investor relations site, with an archive accessible later that day. Medtronic continues to lead in healthcare technology, addressing over 70 health conditions globally.
